百克生物：流感病毒裂解疫苗（BK-01佐剂）临床试验申请获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for a clinical trial of its influenza virus split vaccine (BK-01 adjuvant), targeting individuals aged 60 and above to prevent influenza caused by the virus [1] Group 1 - The vaccine is designed specifically for the elderly population, which is at higher risk for influenza complications [1] - The vaccine utilizes a split virus technology route combined with a self-developed adjuvant to enhance immunogenicity [1] - Successful development of this vaccine will enrich the company's influenza vaccine research pipeline and provide new vaccination options for the elderly [1]